University Health Network (UHN) includes the Princess Margaret Cancer Centre (PM Cancer Centre), Toronto General Hospital (TGH), Toronto Rehab (TR), Toronto Western Hospital (TWH) and the Michener Institute for Education at UHN. It has five research institutes: Krembil Research Institute (Krembil), PM Cancer Centre, Techna Institute for the Advancement of Technology for Health (Techna), Toronto General Research Institute (TGRl) and Toronto Rehabilitation Institute (TRI). The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. UHN is a research hospital affiliated with the University of Toronto (UT) and a member of the Toronto Academic Health Science Network (TAHSN).
# Breaking Barriers. Building Health.

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Message</td>
<td>2</td>
</tr>
<tr>
<td>The origin of a macrophage</td>
<td>4</td>
</tr>
<tr>
<td>Finding the right path</td>
<td>6</td>
</tr>
<tr>
<td>One of these is not like the others</td>
<td>8</td>
</tr>
<tr>
<td>More than just clowning around</td>
<td>10</td>
</tr>
<tr>
<td>Guiding light for cancer surgery</td>
<td>12</td>
</tr>
<tr>
<td>Bringing it all together</td>
<td>14</td>
</tr>
<tr>
<td>Year in Funding</td>
<td>16</td>
</tr>
<tr>
<td>Year in Discovery</td>
<td>18</td>
</tr>
<tr>
<td>Discoveries to Reality</td>
<td>20</td>
</tr>
<tr>
<td>Research Distinctions</td>
<td>22</td>
</tr>
<tr>
<td>UHN Foundations</td>
<td>24</td>
</tr>
<tr>
<td>Research Institutes</td>
<td>28</td>
</tr>
<tr>
<td>Research Committees</td>
<td>40</td>
</tr>
<tr>
<td>External Sponsors</td>
<td>42</td>
</tr>
<tr>
<td>Financials</td>
<td>44</td>
</tr>
<tr>
<td>Research Trustee &amp; Advisory Boards</td>
<td>46</td>
</tr>
</tbody>
</table>
A surgeon, an engineer and a physicist are sitting at a bar—you may think a joke is coming but what they are discussing is deadly serious: how to detect residual cancer cells left behind after a primary tumour is resected. Failure to remove or kill these cells allows the cancer to recur. However, by applying their collective knowledge they devise, and eventually test, a device that replaces normal visible light with infrared light and the lurking cancer cells are revealed.

Even a wider mix of talent, including health services researchers, health care professionals, community clinicians, patient advocates, pharmacists, and IT specialists, came together to visualize and implement SCOPE (Seamless Care Optimizing the Patient Experience), a revolutionary virtual interprofessional health team program that aims to improve the patient experience by supporting primary care providers through a single point of access.

These are but two examples of the integrated actions that take place every day at UHN. More than 4,000 people engage in research and their expertise spans nearly all aspects of biomedical sciences, including biology, chemistry, physics, engineering, health services, informatics…and the list goes on. As our understanding of the complexity of human disease has increased it has become abundantly clear that our only hope at making…
Despite these challenges, the imperative to break barriers, share information and integrate different skill sets is growing. One can see this in something as routine as analysis of data—every year new techniques and tools are developed that allow our researchers to more deeply probe the nature of normal and diseased cells and tissues. By adopting high-throughput technology able to analyze genes, proteins, cells and populations, the volumes of data collected can only be understood by similarly robust information analysis tools. Only by the application of these still evolving processes will critical relationships buried in complex datasets be revealed.

We hope that you enjoy this year’s report, which is all about how UHN breaks down barriers, integrates expertise and shares knowledge for better health.
The origin of a macrophage
Study traces the “big bang” moment for certain immune cells

Let’s go back to the beginning. We each developed from one cell. This single cell went through rounds and rounds of divisions, creating daughter cells with the same genetic material that eventually make up the distinct organs and tissues in the body.

But clearly, brains, muscles and bones are very different from one another. Given that these specialized organs arose from a common ancestor cell, this raises the question as to the moment at which each of the estimated 37.2 trillion cells in the human body had its “big bang”—fulfilling its destiny of becoming a brain cell, muscle cell or bone cell.

Dr. Clinton Robbins (pictured above) set out to provide new insight on this subject. He focused on uncovering the origin of immune cells that reside in blood vessels—known as arterial macrophages.

His research team analyzed the genetic profiles of macrophages at different stages of life. Using various ‘fate mapping’ techniques, which involve tracing the lineage of cells during development in the womb or after birth, they found that arterial macrophages actually have different origins depending on age.
In the embryo, arterial macrophages come from a partially developed ‘precursor’ cell that expresses a specific protein on its cell surface, known as CX3CR1. Immediately after birth, however, they originate from a different type of cell, an immune cell known as a monocyte that comes from the bone marrow. Finally, in adulthood, arterial macrophages gain the ability to divide and regenerate; this enables them to increase in number in the absence of both precursor cells and monocytes.

“Our findings underscore the need for more careful examination of the factors that maintain macrophages in tissues,” explains Dr. Robbins. “Insights from these studies are critical for research into diseases such as atherosclerosis, the underlying cause of virtually all heart diseases. In atherosclerosis, macrophages accumulate in the arteries and lead to the formation of lesions that interfere with blood flow; determining where these macrophages come from and how they accumulate will help identify new ways to stop or slow this process.”

Tracing the origin of a cell type helps to understand its role in health and disease.

Ensan S, et al. Nat Immunol. 2016 Feb. This work was supported by the Canadian Institutes of Health Research, the Ontario Lung Association and the Toronto General & Western Hospital Foundation. C Robbins is the Peter Munk Chair in Aortic Disease Research, M Cybulsky holds a Tier 1 Canada Research Chair in Arterial Wall Biology and Atherogenesis and A Gramolini holds a Tier 2 Canada Research Chair in Cardiovascular Proteomics and Molecular Therapeutics.
Finding the right path
Peptides guide developing nerves toward brain vision centres

When light hits our eyes, it is transformed into an electrical signal. That signal travels along a specialized cable—the optic nerve—to specific brain regions that transform it into images, allowing us to see.

The optic nerve is not just one nerve, but is composed of around 1.5 million nerve fibres called retinal axons. In order for the vision system to function, these retinal axons must be guided and connected to highly specific brain regions—a process that occurs during development and is not well understood.

The process of brain development mirrors the complexity of the human brain: billions of cells are born, grow and connect with each other. These connections, which form the basic brain architecture required for us to interact with the world around us, are made possible by signalling molecules, including peptides (i.e., molecules that are similar to proteins, but smaller). These compounds serve as beacons that guide how cells interact with each other.

Retinal axons can be damaged or lost in conditions like glaucoma, leading to irreversible blindness. A major barrier to treatment is a better understanding of how developing nerve fibres connect with the brain regions responsible for processing vision, including the optic tectum.
Recent findings from the lab of Dr. Philippe Monnier addressed this problem by shedding light on how retinal axons are able to navigate the maze-like environment of the developing brain. The research team found that two types of signalling molecules within the Repulsive Guidance Molecule a (RGMa) family of peptides serve important yet opposing functions. The N-RGMa subtype promotes deep projections, ensuring that developing axons extend far enough into the optic tectum, while the C-RGMa subtype prevents growing axons from extending too far. Together, these peptides ensure that developing nerve fibres from the eye find the optic tectum layer. “Our work has uncovered the peptides responsible for ensuring that retinal axons integrate into the correct layer of the optic tectum. N-RGMa serves as the gas pedal for axonal growth, while C-RGMa serves as the brake. These insights may help in the development of therapies aimed at repairing retinal axon damage,” remarks Dr. Monnier.

Image: Dr. Monnier is depicted enjoying art—an act that would be impossible without the correct neuronal connections. The paintings feature two trainees that contribute to Dr. Monnier’s research program (L-R: Hidekiyo Harada; Jason Charish). Superimposed over Jason Charish’s portrait is an illustration that emphasizes the maze-like complexity of the path linking the optic nerve with the visual centres in the brain.

Banerjee P, et al. Cell Death Differ. 2016 Mar. This work was supported by the Canadian Institutes of Health Research, the University of Toronto Vision Science Research Program and the Toronto General & Western Hospital Foundation.
One of these is not like the others

Drug targets cancer cells by mimicking viral infection

Things are not always what they seem. That was what a team of researchers led by Dr. Daniel De Carvalho found when they decided to explore how a group of anticancer drugs, known as DNA-demethylating agents, target cancer cells. DNA-demethylating agents are approved for use in some blood cancers and are under evaluation for treating different types of solid tumours, including colorectal cancer. Despite their use clinically, there has been ongoing debate about the mechanisms that underlie their clinical efficacy.

Specifically, Dr. De Carvalho’s team explored how a DNA-demethylating agent known as decitabine targets colorectal cancer stem cells. These cancer stem cells are believed to be responsible for disease relapse because they are resistant to treatment and can multiply indefinitely. By targeting these cells, decitabine has the potential to improve patient outcomes for colorectal cancer.

Dr. De Carvalho’s team found an unlikely mechanism of action: the drug works by making the cells proliferate more slowly and behave like they are infected with viruses. As a consequence of this, the cells are targeted and cleared by the immune system.
Importantly, the researchers found that this strategy is effective against the hard-to-target colorectal cancer stem cells.

“By mimicking a viral infection, the immune system is tricked into ‘seeing’ the cancer cells as an infection that needs to be destroyed,” says Dr. De Carvalho. “Our work demonstrates that viral mimicry is a viable anti-tumour strategy.” Currently colorectal cancer recurs in about half of patients and is among the top three types of cancer diagnosed in Canada.

Future studies will be focused on determining whether combining viral mimicry with cancer immunotherapy—a treatment that stimulates the immune system—provides more clinical benefits than either therapy alone.

Cancer cells treated with the drug behave like they are infected with viruses.
More than just clowning around
Helping hands that enrich the lives of people with dementia

“There is no pill that can do this,” says Dr. Pia Kontos, referring to the findings of her study that evaluated the effect of elder-clowns on people living with dementia.

Dementia can lead to deficits in memory, language, attention, reasoning and judgement. Often, people living with this illness can become agitated, depressed and apathetic. Given that medications can alleviate only some of these symptoms and can have harmful side effects, researchers are investigating alternative approaches. A recent innovation in arts-based approaches to dementia care is the introduction of elder-clowns into nursing homes. Elder-clowns are professional performers who specialize in the art of clowning with individuals living with dementia. In addition to completing formal studies in acting and the clowning arts, elder-clowns receive training on how to interact with older adults living with dementia. Unlike their circus counterparts, they wear minimal make-up and colourful dress from the 1950s.

Elder-clowns are brought into nursing homes to enrich the lives of older adults with dementia by lessening social isolation, and providing opportunities to express creativity, playfulness and imagination. Their interactions with residents can include verbal, physical
and musical jests that incorporate humour, storytelling and empathy. Importantly, elder-clowns tailor their interaction to the life histories of each person and to the person’s mood and responsiveness during each visit.

While the art of clowning was adapted for the dementia population in the 1990s, there is limited knowledge of its impact. To explore this issue, Dr. Kontos led a study in which four elder-clowns visited 23 nursing home residents living with moderate to severe dementia.

Dr. Kontos and her colleagues found significant reductions in agitation and increased quality of life in residents after 12 weeks of biweekly elder-clown visits. They also observed that residents would respond to the elder-clowns and engage with them by being deliberately funny, playful and imaginative. The residents also expressed sadness, which is typically suppressed in conventional dementia care, but was instead validated and supported by the clowns.

The findings of the study were two-fold: it revealed that elder-clowning provides therapeutic benefits and dispelled the myth that people living with dementia are incapable of meaningful interactions. By showing that elder-clowning can provide real benefits, these findings will inform new care approaches that aim to improve quality of life and enrich the lives of people living with dementia.

Image: (R-L) Dr. Kontos, and elder-clowns Kathleen Le Roux and Phil Koole. When visiting nursing home residents, elder-clowns bring along ukuleles and other props to support their interactions.

Nanoparticles combine imaging approaches to target tumours

Advanced imaging techniques are essential innovations to help guide the removal of tumours. Precisely identifying and removing a tumour is especially challenging in head & neck cancer where the anatomy is complex and full of sensitive ‘at risk’ organs. Prior to cancer surgery, X-ray computed tomography (CT) is often used to construct a detailed three-dimensional image to help the surgeon visualize the tumour within complex healthy structures and to plan the optimal surgical procedure for removal. Another imaging technique called fluorescence optical imaging is also being increasingly used for guidance during surgery, to identify and locate cancer that has spread to the lymph nodes.

Until now, the combined use of these techniques in the operating room for tumour and lymph node visualization has been limited because multiple imaging agents are needed, and existing agents do not have the sensitivity and specificity needed for disease detection. Dr. Jinzi Zheng and her collaborators have found a way to improve the usefulness of these imaging methods by developing a single injectable imaging agent that can be used for both modalities.

Dr. Zheng and her team developed the agent by encapsulating, into a single nanoparticle, different imaging molecules that were engineered for use in CT and fluorescence imaging. Data obtained from ten different experimental cancer models showed that the
new imaging agent improved sensitivity when locating the tumour, its boundaries and lymph nodes where the cancer had infiltrated.

Explains Dr. Zheng, “This new technology is particularly useful because it enables us to employ different imaging techniques prior to and during surgery following one injection of the imaging agent. Our results are particularly promising and suggest that this agent could be used to improve the localization, detection and removal of a wide range of cancers.”

Using a nanoparticle as the carrier also ensured that the agents remained in the tumour long enough for pre- and intra-operative imaging. This is because nanoparticles exploit defects in a tumour’s blood vessels to increase their retention within the body. The nanoparticle components are individually approved with proven efficacy, which should help to accelerate the translation of this development into clinical practice.

Ironically, the need for such advanced tumour imaging agents is driven by improvements in screening and diagnosis. Finding disease earlier is better for the patient’s outcome, but challenges surgeons to remove tiny tumours that are often too small to find by touch. Advances in the use of X-ray CT imaging technology during surgery also creates a need for an agent that stays in the tumour for a long time, which is a natural property of the liposomes developed by Dr. Zheng.

Zheng J, et al. Biomaterials. 2015 Oct. This work was supported by the Fidani Family Chair in Radiation Physics, the Kevin & Sandra Sullivan Chair in Surgical Oncology, the RACH Fund and The Princess Margaret Cancer Foundation.
Bringing it all together
New leadership takes research enterprise to the next level

Five research institutes. Almost one million square feet of dedicated research space. Over one thousand world-class researchers. Given UHN’s standing as Canada’s largest research hospital, leading an initiative to Break Barriers and Build Health is no small task.

Dr. Brady Wouters—UHN’s new Executive Vice President, Science and Research—is up to that challenge.

Dr. Wouters assumed the role in October 2016 following a highly competitive international search; but he is already well known throughout UHN, having been at the institution for almost a decade. He was recruited from Maastricht University to PM Cancer Centre as a Senior Scientist in 2008, and he also served as PM Cancer Centre’s interim Director of Research from 2014 to 2016. His experience in these roles will undoubtedly help to achieve his vision: to build a more cohesive research enterprise.

“I’m excited to create opportunities that bring the organization closer together,” explains Dr. Wouters. “I’m a big believer in group intelligence and team science, and I think that this is really UHN’s competitive advantage. Our individual researchers are great, but they would be great anywhere by themselves. It’s the environment that elevates research opportunities and innovation to another level. This is one of the things that we’re going to be working on: eliminating the divisions that impede team science and fostering the unique environment and synergistic relationships that accelerate integrative research across the institution.”

He also sees an opportunity to promote a unified culture of research across UHN as a whole. “It’s time for us to realize the idea of a research hospital—as envisioned by Dr. Chris Paige—and to really incorporate research into everything that we do at UHN.” A starting point for this is to capitalize on the valuable information that is constantly being generated at UHN, such as that from diverse sources like heart monitors, genomic sequencers, ultrasound machines and patient questionnaires. One of Dr. Wouters’ initial areas of focus will be to find new ways of capturing, interpreting and unifying data—and weaving them seamlessly into the fabric of the organization—to help secure UHN’s growth in this era of data-driven discovery.

Research is what defines us; it’s what makes us different.

“The mission at UHN is really twofold: to deliver the best possible care with the knowledge that we have today and to recognize the limitations of our current treatments in order to develop new solutions for tomorrow. Research is the only tool we have to do this. That’s why I support research across the entire spectrum: from curiosity-driven discovery research that reveals new insights into human biology to transformational clinical trials, health services research or rehabilitation programs that are changing policy and the way that the government funds medicine. Research is what defines us; it’s what makes us different, and I can’t wait to see what we can accomplish when we face today’s greatest health issues together.”
Applying Genomics to Fight Leukemia

Dr. Jean Wang was awarded $3.4 million from Genome Canada’s Genomic Applications Partnership Program (GAPP). The program supports research and development projects in genomics that address real-world challenges and opportunities.

Leukemia is one such challenge: standard chemotherapy treatments for the disease are not completely effective. These regimens, which have remained essentially unchanged since the 1970s, do not completely destroy all of the leukemia cells—enabling them to re-grow and lead to cancer recurrence.

To address this, Dr. Wang will use the GAPP funds to advance a promising therapeutic drug for leukemia towards clinical trials. The agent, called SIRP-alpha-Fc, interferes with a protein called CD47 that is found on the surface of leukemia cells. CD47 shields the cells from the host’s immune system, enabling the leukemia cells to evade destruction; by blocking CD47, SIRP-alpha-Fc removes this protection and signals immune cells called macrophages to engulf and destroy leukemia cells.

The project is a collaborative effort that brings together Dr. Wang, Dr. Jayne Danska (an immunogeneticist at SickKids) and Trillium Therapeutics Inc. (a biotech company based in Toronto). It was one of five projects nationwide to be awarded funding from this GAPP round.
Federal Funding for Patient-Oriented Research

UHN scientists are playing key roles in two of the five Strategy for Patient-Oriented Research (SPOR) Networks in Chronic Disease funded this year. Awarded through the Canadian Institutes of Health Research, the networks received $12.4 million each to develop transformative and measurable improvements for patients with chronic disease.

The Chronic Pain SPOR Network will bring together researchers from Krembil Research Institute, Toronto General Research Institute and Techna to enhance access to care for those suffering from chronic pain and to advance the translation of research into clinical practice.

The Diabetes and its Related Complications SPOR Network, led by UHN’s Dr. Gary Lewis, will create a national registry and risk assessment tools to develop effective, evidence-based tests and preventative strategies for diabetes and its related diseases.

Investment in Cancer Stem Cell Research

A research project led by Dr. John Dick was awarded $6.2 million over five years from the highly competitive Terry Fox New Frontiers Program Project Grant. The award will be used to advance our understanding of cancer stemness, which is the ability of cancer cells to self-renew and generate more cancer cells. The project will be focused on uncovering ways to improve the detection and treatment of three high-risk cancers: acute myeloid leukemia, myeloma and brain cancer.

Securing Cutting-Edge Infrastructure

Through its John R. Evans Leaders Fund, the Canada Foundation for Innovation announced funding for over $1.5 million in infrastructure to advance research at UHN. These projects have diverse aims: overcoming immunosuppression to fight infections and cancer; defining the role of macrophages in cardiovascular disease; examining retinal development, injury and repair; preventing falls in vulnerable populations; targeting mitochondrial dysfunction in leukemia; and unravelling the mechanisms of joint damage in osteoarthritis.
Ankylosing spondylitis (AS) is a form of arthritis that commonly affects the spine. In addition to suffering from chronic back pain, people with AS are at increased risk of heart disease and stroke; however, it is not clear whether these people are also at risk for mortality as a consequence of these events. A recent study led by Dr. Nigil Haroon addressed this gap in knowledge. His research team analyzed health data from over 21,000 patients and found that those with AS are at higher risk for death from heart disease and stroke than those without AS. Major risk factors for death include age and chronic kidney disease. This indicates that screening and treating modifiable risk factors could help prevent vascular disease in people with AS. Haroon NN, et al. Ann Intern Med. 2015 Sept.

Chemotherapy is an effective treatment for early stage breast cancer. Despite this, studies have shown that certain drugs can increase the risk of heart failure in older women (>65). To date, these studies have not addressed whether these risks affect younger women (<65)—a demographic that comprises the majority of people diagnosed with the disease. To determine whether younger women are also at risk, Dr. Paaladinesh Thavendiranathan analyzed the health data of 18,540 women over the age of 18 that were treated for early-stage breast cancer. He found that all women treated with chemotherapy—regardless of age—are at increased risk for heart failure. He cautions that the benefits of chemotherapy far outweigh the risks, and that monitoring younger women for heart disease may help curb these risks. Thavendiranathan P, et al. J Clin Oncol. 2016 Jul.
Two Sides to Recovery
Recovering from treatment in the intensive care unit (ICU) is challenging. Dr. Margaret Herridge found that the success of ICU recovery could be predicted based on a patient’s age and length of stay in the ICU. This model could help tailor long-term rehabilitation plans. A complementary study by Dr. Jill Cameron focused on the challenges faced by caregivers of recovering ICU patients. She found that caregivers experienced clinical depression, which in some cases did not improve up to one year later. These studies highlight the need to consider the experiences of the patient—and the caregiver—during ICU recovery.


Research Tool Senses Damage
The production of energy in the body is essential, but it also generates by-products called reactive oxygen species (ROS). If left unchecked, ROS can cause significant damage to cells. Fortunately, antioxidant pathways ‘scavenge’ ROS and stop harmful effects. To help researchers study these processes, Dr. Jonathan Rocheleau developed a molecular sensor that reveals the balance between ROS and antioxidant pathways in a cell. The sensor, called Apollo-NADP+, measures this balance with higher accuracy and precision than existing systems. This tool will help shed light on a wide range of diseases associated with ROS, which include diabetes and age-related cancers. Cameron WD, et al. Nat Methods. 2016 Apr.

Excess Fluids Affect Sleep
People with end-stage renal disease (ESRD) have malfunctioning kidneys and have to regularly undergo dialysis to manage fluid buildup. These people also often have sleep apnea, a potentially serious disorder in which breathing repeatedly pauses during sleep. One explanation for this may be that excess fluids shift from the legs towards the head when lying down—restricting the airway. To test this possibility, Dr. T Douglas Bradley used a method called ultrafiltration to remove excess fluid in people with ESRD. He found that this markedly improved sleep and reduced symptoms of sleep apnea. This suggests that targeting fluid buildup is a potential treatment for sleep apnea. Lyons OD, et al. Am J Respir Crit Care Med. 2015 Jun.

Overcoming Tumour Resistance
Glioblastoma is a brain cancer that is particularly resistant to treatment. This is partly due to a subtype of tumour cells that are capable of replicating themselves. Exactly what enables some glioblastoma cells to regenerate is unknown. Drs. Mathieu Lupien and Peter Dirks (SickKids) have shed light on this by exploring the function of a protein called MLL5. They found that in glioblastoma cells, MLL5 represses the levels of another protein known as H3.3. In turn, reduced H3.3 levels were found to cause DNA to become more compact, which turns on genes involved in tumour regeneration. The team also identified two chemical compounds that may prevent this process. Further development of these compounds may lead to new drugs to treat this aggressive type of cancer. Gallo M, et al. Cancer Cell. 2015 Dec.
AVROBIO Launches Gene Therapy Programs

The UHN spinout company AVROBIO launched two programs based on research by Drs. Christopher Paige and Jeffrey Medin (now at the Medical College of Wisconsin). The programs—which are ready for Phase I clinical trials—leverage cell and gene therapy platforms for cancer and rare diseases.

The first program is developing a therapy that triggers the immune system to detect and destroy cancer cells. A patient’s cancer cells are isolated and genetically modified to produce an immune signalling molecule called IL-12. The modified cells are then infused back into the patient; as they begin producing IL-12, the immune system is activated to target and eliminate the cancer cells.

The second program is developing a similar approach to treat Fabry disease, a rare genetic disorder. People with Fabry disease have genetic mutations that lead to reduced levels of the enzyme alpha-galactosidase A. Deficiencies in this enzyme result in defects in metabolism that can cause pain, kidney failure and heart disease. AVROBIO’s therapy involves isolating cells from a Fabry disease patient, modifying them by introducing a functional copy of the gene and infusing them back into the patient.

Cell and gene therapy platforms may offer innovative therapies for patients with cancer and Fabry disease.

AVROBIO raised $25 million in Series A financing, co-led by Atlas Venture, Clarus and SV Life Sciences, towards accelerating the development of these programs.
Medication Labelling System Licensed
A medication labelling system co-invented by Drs. Ludwik Fedorko and Joe Fisher was licensed to Assure Medical Systems Inc.—a start-up company co-founded by Dr. Fedorko. The system uses electronic barcoding to label the medications that will be delivered via syringes during surgeries. Each label is automatically populated with information including the drug name, concentration and time of preparation. As such, the system significantly reduces the risks of labelling errors and misinterpretation that arise from traditional hand-written labels—improving patient safety.

UHN Companies Awarded JLABS Residency
Two UHN-based startup companies, AVROBIO and Nanovista, were awarded residency at JLABS @ Toronto, Johnson & Johnson Innovation’s life sciences incubator. Located in the MaRS Discovery District, the facility houses 40,000 sq. ft. of space for emerging companies to move products along the path to commercialization.

Nanovista is developing multimodal visualization agents that are designed to improve the performance of image-guided high-precision cancer therapies. The early-stage company was co-founded by Drs. Jinzi Zheng, David Jaffray and Christine Allen (UT).

AVROBIO is focused on developing novel gene therapies for cancer and rare diseases. It was founded based on the work of Drs. Paige and Medin (see page 20).

UHN’s Inventor of the Year 2015
This annual award was presented to creators of BresoDx®—a device that is used to diagnose sleep apnea at home—by UHN’s office of Technology Development and Commercialization (TDC). At UHN’s annual general meeting, TDC’s Dr. John Reid (pictured third from the left) presented the award to (L- R) Drs. Geoff Fernie, T Douglas Bradley and Hisham Alshaer.

Because diagnosis of sleep apnea is traditionally carried out in a sleep laboratory, few people undergo testing. The wireless, at-home features of BresoDx® help overcome this barrier. The device is licensed to BresoTec Inc. and has received regulatory approval from Health Canada.
Research Distinctions
Selected honours bestowed upon UHN researchers

Dr. Cheryl Arrowsmith
Fellow, American Association for the Advancement of Science

Dr. Joanne Bargman
2016 International Distinguished Medal, National Kidney Foundation

Dr. Tom Chau
2016 Jonas Salk Award, March of Dimes Canada

Dr. Angela M Cheung
Tier 1 Canada Research Chair in Musculoskeletal and Postmenopausal Health

Dr. Hance Clarke
2016 Early Career Award, Canadian Pain Society

Dr. Angela Colantonio
Fellow, Canadian Academy of Health Sciences

Dr. Myron Cybulsky
Tier 1 Canada Research Chair in Arterial Wall Biology and Atherogenesis

Dr. Abdallah Daar
Fellow, African Academy of Sciences

Dr. Tirone David
2016 Scientific Achievement Award, American Association for Thoracic Surgery

Dr. John Dick
2016 Fellow, American Association for Cancer Research Academy

Dr. Eleanor Fish
Fellow, African Academy of Sciences

Dr. Herbert Gaisano
Member, Order of Ontario

Dr. Mary Gospodarowicz
2016 O. Harold Warwick Prize, Canadian Cancer Society

Dr. Robin Green
Tier 2 Canada Research Chair in Traumatic Brain Injury – Cognitive Rehabilitation Neuroscience (Renewal)

Dr. Nigil Haroon
2016 Young Investigator Award, Canadian Rheumatology Association

Dr. Susan Jaglal
Fellow, Canadian Academy of Health Sciences

Dr. Kevin Kain
Tier 1 Canada Research Chair in Molecular Parasitology (Renewal)

Dr. Marianne Koritzinsky
2016 Michael Fry Research Award, Radiation Research Society

Dr. Ren-Ke Li
Fellow, International Academy of Cardiovascular Sciences
Dr. Aravind Namasivayam
2016 Excellence in Applied Research Award, Speech-Language & Audiology Canada

Dr. Pamela Ohashi
Tier 1 Canada Research Chair in Tumour Immunity and Immunotherapy (Renewal)

Dr. Milica Radisic
2015 Hatch Innovation Award, Canadian Society for Chemical Engineering

Dr. Frank Rudzicz
2016 Excellence in Applied Research Award, Speech-Language and Audiology Canada

Dr. Michael Sefton
2016 Terumo Global Science Prize, Terumo Foundation for Life Sciences and Arts

Dr. Frances Shepherd
Officer, Order of Canada

Dr. Katherine Siminovitch
Fellow, Canadian Academy of Health Sciences

Dr. Catriona Steele
2016 Lifetime Achievement Award, Speech-Language & Audiology Canada

Dr. Antonio Strafella
Tier 2 Canada Research Chair in Movement Disorders and Neuroimaging (Renewal)

Dr. Murray Urowitz
Lifetime Achievement Award, Lupus Ontario

Dr. Pascal van Lieshout
2016 Excellence in Applied Research Award, Speech-Language & Audiology Canada

Dr. Donald Weaver
Tier 1 Canada Research Chair in Drug Design for Protein Misfolding Disorders

Dr. Daniel Winer
Tier 2 Canada Research Chair in Immunometabolism

Dr. Gang Zheng
Fellow, American Institute for Medical and Biological Engineering
UHN Foundations

The Princess Margaret Cancer Foundation

Toronto General & Western Hospital Foundation

Toronto Rehab Foundation
The Princess Margaret Cancer Foundation

**Billion Dollar Challenge: the Home Stretch**

In April 2012, The Princess Margaret Cancer Foundation (The PMCF) embarked on the largest single fundraising campaign in the history of Canadian health care—the Billion Dollar Challenge. This five-year initiative aims to secure $1 billion to enable personalized cancer medicine at The Princess Margaret Cancer Centre.

The PMCF has met this challenge ahead of schedule: in January 2017, the Foundation announced that a total of $1,052,000,000 has been raised, with $532 million coming from philanthropy and $520 million from grants secured by cancer centre researchers.

The Foundation also achieved a new record in net annual fundraising with a total of $104 million raised. This includes $15.5 million raised for the $50 million Research Campaign, which launched in 2015.

For the second consecutive year, The PMCF raised an all-time record of $24.8 million in net income from its lotteries through continuous innovation in ticket purchase options, prizing and use of social media to reach more people. The Enbridge Ride to Conquer Cancer had another strong year, raising over $19.3 million with 4,853 riders and OneWalk to Conquer Cancer made its debut with 4,523 participants raising over $7.7 million.

Thanks to the cancer research enabled through these programs and the generosity of the community, the landscape in cancer diagnosis and treatment is changing rapidly. The Tumour Immunotherapy Program led by Drs. Pamela Ohashi and Lillian Siu is an excellent example of how The Princess Margaret is leading the way in personalized cancer medicine by testing promising new cancer therapies. This treatment harnesses the natural power of the immune system to combat cancer growth, and is an emerging anticancer strategy has already been shown to be effective at improving patient outcomes.

*Left photo: The inaugural OneWalk to Conquer Cancer fundraiser united a powerful community of cancer survivors and their supporters to raise money for cancer research. Right photo: An RCMP officer at the 2016 Billion Dollar Challenge event.*
Renamed Krembil Research Institute Honours Donor Giving

The Krembils—Bob, Linda, Mark, Jake and Stacey—are among Canada’s leading investors in research. Their philanthropic support of Toronto Western Hospital began with a gift that established the Krembil Family Chair in Neurology. That gift was a catalyst for building a world-leading research program bar none.

Nearly 20 years and $80 million later, that beacon of excellence now exists with the renaming of Toronto Western Hospital’s research arm to the Krembil Research Institute (or simply ‘Krembil’)—branding that coincided with a new, multi-million dollar pledge from the family last fall.

On November 13, 2015, Her Royal Highness, Sophie, The Princess Edward, Countess of Wessex, patron of Toronto Western Hospital, acknowledged the family’s generosity at a tribute event unveiling the Institute’s new name.

“Our world-leading scientists now have a renewed sense of pride in their life’s work to find cures for diseases of the brain, spine, bones, joints and eyes,” she said. “And it will bring tremendous hope to our patients who will ultimately be the beneficiaries of discovery research.”

Dr. Donald Weaver, Krembil’s Director, sees the Krembil family’s commitment as a driving force behind work in the Institute’s state-of-the-art laboratories. “We have a saying here at Krembil: If we’re not here to find a cure, then why the hell are we here? The Krembils chuckle every time I say it, but there’s an understanding between us. They know the phrase is not hyperbole, and every time we get a little closer to solving the mystery of these diseases, we can honestly say that it’s a combination of great science and great philanthropy that will help patients live not just longer, but better lives.”

*Photo (L-R): Mark Krembil; Stacey Krembil; Lieutenant-Governor Elizabeth Dowdeswell; Jake Krembil; Sophie, The Princess Edward, Countess of Wessex; Linda Krembil; and Bob Krembil.*
Accelerating Concussion Treatment and Research

Toronto Rehab’s new and unique Hull-Ellis Concussion and Research Clinic sees patients within one week of sustaining a brain injury—providing care and management of their symptoms, and enabling research on their progress.

Donor support—including the TWINS Gala that raised $700,000—enabled the clinic to come to fruition. The Hull-Ellis Clinic, aptly named in honour of hockey legends Dennis Hull and Ron Ellis, provides patients with a weekly assessment and comprehensive care program, as well as follow-ups at weeks 8, 12 and 16 post-injury. In addition to physician assessments, other assessments that measure cognition, balance and mobility, and mood and personality are conducted.

“Our goal is to find faster ways to help people recover and to prevent long-term complications of traumatic brain injury,” explains Dr. Mark Bayley, Medical Director of the Brain & Spinal Cord Injury Research Program, who leads the clinic. “We want to identify the people who have the most challenging symptoms and accelerate their recovery. Our rigorous evaluation of techniques and treatments will enable the development of a best practice model that others can emulate across the province, country and globally.”

To celebrate the first anniversary of the Hull-Ellis Clinic at Toronto Rehab in June, donors and volunteers joined Ron Ellis for breakfast and an informative session titled Concussion Across the Spectrum of Injury. The session provided attendees with key information about the resource and equipment needs required to advance the research mandate of the clinic.

Through donor support, scientists and clinicians are making an incredible difference in the lives of people who have experienced concussion and brain injury. Our community of supporters plays a key role in helping Toronto Rehab uphold its position as the number one rehabilitation research centre in the world.

Photo: (L-R) Ron Ellis and Dennis Hull cut the ceremonial ribbon to officially open the Hull-Ellis Concussion and Research Clinic.
UHN Research Institutes

Krembil Research Institute

Princess Margaret Cancer Centre

Techna Institute

Toronto General Research Institute

Toronto Rehabilitation Institute
Research Council

**Director and Chair, Krembil Research Institute** Donald Weaver  
**Co-Director, Donald K. Johnson Eye Institute** Valerie Wallace  
**Division Head, Healthcare Outcomes & Research** Elizabeth Badley  
**Division Head, Fundamental Neurobiology** Peter Carlen  
**Division Head, Brain, Imaging & Behaviour – Systems Neuroscience** Karen Davis  
**Division Head, Genetics & Development** James Eubanks  
**Division Head, Orthopaedics: Director, Arthritis Program** Nizar Mahomed  
**Clinical Representative, Arthritis Program** Robert Inman  
**Chair, Trainee Affairs Committee** Frances Skinner  
**Executive Director, Research Operations** Lisa Alcia  
**Senior Vice President, UHN and Executive Lead, TWH (Interim)** Janet Newton  
**Executive Vice President, Science and Research** Christopher Paige  
*role filled by Bradley Wouters as of Oct 1, 2016

Researchers

**Brain, Imaging & Behaviour-Systems Neuroscience**

**Senior Scientists**  
Jonathan Brotchie  
Robert Chen  
Karen Davis  
William Hutchison  
Sidney Kennedy  
Andres Lozano  
Mary Pat McAndrews  
David Mikulis  
Antonio Strafella

**Scientists**  
Jonathan Downar  
Mojgan Hodaie

**Affiliate Scientists**  
Jonathan Dostrovsky  
Mark Guttmann  
Walter Kucharczyk

**Fundamental Neurobiology**

**Senior Scientists**  
Peter Carlen  
Frances Skinner

**Scientists**  
Shuzo Sugita  
Michael Tymianski  
Donald Weaver

**Emeritus**  
Charles Tator

**Senior Scientists**  
Cathy Barr  
James Eubanks  
Michael Fehlings  
Robert Inman  
Mohit Kapoor  
Philippe Monnier  
Lyanne Schlichter  
Elise Stanley  
Florence Tsui

Krembil Research Institute  
*formerly the Toronto Western Research Institute*

Senior Scientists 36  
Scientists 12  
Affiliate Scientists 16  
Emeritus 2  
Clinician Investigator 31  
**Total Appointed Researchers** 97  
Clinical Researchers 122  
**Total Researchers** 219

Research Space 146,568 sq. ft.  
**Total Staff** 275

External Funding $41,203,837  
**Publications** 901

Fellows 42  
Graduate Students 76  
**Total Trainees** 118
Joan Wither
Scientists
W Mark Erwin
Nigil Haroon
Lorraine Kalia
Suneil Kalia
Armand Keating
Affiliate Scientists
Arjun Sahgal
Sowmya Viswanathan

Health Care & Outcomes Research
Emeritus
Murray Urowitz
Senior Scientists
Elizabeth Badley
J David Cassidy
Aileen Davis
Dafna Gladman
Nizar Mahomed
Scientist
Anthony Perruccio
Affiliate Scientists
Vinod Chandran
Cheryl Cott
Paul Fortin
Monique Gignac
Rosemary Martino

Patient-based Clinical Research
Senior Scientists
Anthony Lang
Colin Shapiro

Vector Core
Senior Scientist
Jeffrey Medin

Vision Science
Senior Scientists
Christopher Hudson
Martin Steinbach
Graham Trope
Valerie Wallace
Agnes Wong
Scientist
Jeremy Sivak
Affiliate Scientists
Moshe Eizenman
John Flanagan
Brenda Gallie

Clinician Investigators
Mark Bernstein
Anuj Bhatia
Michael Brent
Daniel Buchman
Melanie Cohn
Robert Devenyi
Dean Eiterman
Alfonso Fasano
Susan Fox
Kenneth Fung
Rajiv Gandhi
Timothy Jackson
Sukhvinder Kalsi-Ryan
Efrem Mandelcorn
Daniel Mandell
Shane McNerney
Roger McIntyre
Renato Munhoz
Laura Passalent
Anahi Perlas
Fayeza Quereshy
Y Raja Rampersaud
David Rootman
Mohammed Shamji
Allan Slomovic
David Tang-Wai
Carmela Tartaglia
Zahi Touma
Christian Veillette
M Elizabeth Wilcox
Mateusz Zuwowski

Clinical Researchers
Ronit Agid
Jamal Ahmad
Danielle Andrade
Yaron Avitzur
Heather Balsey
Paul Binhammer
Jeff Bloom
Claire Bombardier
Arthur Bookman
Vera Bril
Richard Brull
Yvonne Buys
Simon Carette
Leanne Casaubon
Rodrigo Cavalcanti
Jas Chahal
Clara Chan
Vincent Chan
Kenneth Chapman
Caroline Chessel
Angela C Cheung
Angela M Cheung
Ki Jinn Chin
Frances Chung
Maria Cino
Paula Cripps-McMartin
Michael Cusimano
J Roderick Davey
J Martin del Campo
Michael Easterbrook
Sherif El-Defrawy
Richard Farb
David Frost
Fred Gentili
Alberto Goffi
Allan Gordon
Brent Graham
Clement Hamani
Patricia Harvey
Cheryl Jaigobin
Harry Janssen
Sindhu Johnson
Benjamin Kaasa
Rita Kang
Moira Kapral
Hans Katzberg
Ron Keren
Edward Keystone
Kyle Kirkham
Diana Kjenak
Paul Kongkhiam
Stephen Kraft
Timo Krings
Richelle Kruisselbrink
Jeffrey Kwong
Jan Lackstrom
Robert Lam
Wai-Ching Lam
Carolina Landolt-Marticorena
Johnny Lau
Stephen Lewis
Joel Lexchin
Mark Mandelcorn
Pirjo Manninen
Samuel Markowitz
Connie Marras
Theodore Marrs
K Wayne Marshall
Eric Massicotte
Steven McCabe
Kenneth Melvin
Ali Naraghi
Mary Ann Neary
Ahtsham Niazi
Ivy Oandasan
Darrell Ogilvie-Harris
Allan Okrainec
Karen Okrainec
Christian Pagnoux
Philip Peng
Vitor Pereira
Aleksandra Pikula
Atul Prabhu
Arun Prasad
Theodore Rabinovitch
Sidney Radomski
Sapna Rawal
Shail Rawal
Aylin Reid
Lisa Richardson
Rowena Ridout
Cheryl Rosen
David Salonen
Jorge Sanchez-Guerrero
Paul Sandor
Michael Schwartz
Hemant Shah
Sanjay Siddha
Frank Silver
Martin Simons
Shaun Singer
Jeffrey Singh
Mandeep Singh
Sumeet Sodhi
Peter St George-Hyslop
Matthew Stanbrook
Amanda Steiman
Khalid Syed
Peter Tai
Susan Tarlo
Maria Tassone
Karel terBrugge
Karen Tu
Lashmi Venkatraghavan
Herbert von Schroder
Adam Weizman
Richard Wennberg
Robert Willinsky
David H Wong
David T Wong
Jean Wong
Eric Yu
Princess Margaret Cancer Centre

Research Council on Oncology (RCO)

Director, PM Cancer Centre; Chair, RCO; Chair, Executive Committee (Interim) * Bradly Wouters
Executive Committee Mitsuhiko Ikura, Rama Khokha, Pamela Ohashi, Gary Rodin, Aaron Schimmer, Vuk Stambolic, Ming-Sound Tsao, Brian Wilson, Gang Zheng
Chair, Appointments Committee Rama Khokha
Medical Director, Cancer Program Mary Gospodarowicz
Medical Director, Laboratory Medicine Program Runjan Chetty
Head, CCRU Amit Oza
Head, Medical Oncology and Hematology (Interim) Amit Oza
Head, Radiation Medicine Fei-Fei Liu
Chief, Surgical Oncology Jonathan Irish
Executive Director, Research Operations Lisa Alcia
Senior Vice President, UHN and Executive Lead, PM Cancer Centre Marnie Escaf
Executive Vice President, Science and Research ** Christopher Paige

*role filled by Rama Khokha as of Oct 1, 2016. **role filled by Bradly Wouters as of Oct 1, 2016.

Researchers

Senior Scientists
Kenneth Aldape
Cheryl Arrowsmith
Sylvia Asa
Norman Boyd
Robert Bristow
David Brooks
Avijit Chakrabarty
Gerald Devins
John Dick
Sherleen Ezzat
Lucia Gagliese

Razgallah Hakem
David Hedley
Richard Hill
Naoto Hirano
Doris Howell
Mitsuhiko Ikura
Norman Iscove
David Jaffray
Igor Jurisica
Gordon Keller
Rama Khokha
Thomas Kislinger

Lothar Lilge
Fei-Fei Liu
Geoffrey Liu
Mathieu Lupien
Tak Mak
Tracy McGaha
Mark Minden
Benjamin Neel
Pamela Ohashi
Ernol Pai
Christopher Paige
Linda Penn

Senior Scientists 48
Scientists 16
Affiliate Scientists 15
Assistant Scientists 1
Total Appointed Researchers 80
CCRU Members 293
Total Researchers 373

Research Space 388,591 sq. ft.

External Funding $154,058,701

Fellows 91
Graduate Students 103
Total Trainees 194

Total Staff 855
Publications 1,312

Research Council on Oncology (RCO)
Gilbert Privé
Brian Raught
Gary Rodin
Robert Rottapel
Aaron Schimmer
Vuk Stambolic
James Till
Ming-Sound Tsao
I Alex Vitkin
Brian Wilson
Bradly Wouters
Gang Zheng
Camilla Zimmermann

**Scientists**
Laurie Ailles
Scott Bratman
Steven Chan
Ralph DaCosta
Daniel De Carvalho
Kim Edelstein
Benjamin Haibe-Kains
Housheng Hansen He
Michael Hoffman
Jennifer Jones
Marianne Koritzinsky
Nadeem Moghal
Catherine O’Brien
Trevor Pugh
Rodger Tiedemann
Gelareh Zadeh

**Assistant Scientist**
Chris Marshall

**Affiliate Scientists**
Eric Chen
Mary Jane Esplen
Anthony Joshua
C Anne Koch
Paul Kongkham
Jason Moffat
Michael Moran
Michael Reedijk
Paul Rivto
Leonardo Salmena
Michael Sherrar
Sachdev Sidhu
Suzanne Trudel
Jean Wang
Wei Xu

**Cancer Clinical Research Unit (CCRU)**
Ayman Al Habeeb
Hamideh Alasti-Hamed
Zishan Allibhai
Dominick Amato

Eitan Amir
Mostafa Atri
Michael Baker
Subrata Banerjee
David Barth
Eric Bartlett
Andrew Bayley
Nathan Becker
Philippe Bedard
J Robert Beecroft
Akbar Beiki-Ardakani
Alejandro Berlin
Hal Berman
Marcus Bernardini
Lori Bernstein
Mark Bernstein
Andrea Bezjak
Jean-Pierre Bissonnette
Ivan Blasutig
Scott Boerner
Jette Borg
Penelope Bradbury
Anthony Brade
Donald Branch
Savtaq Brar
Stephen Breen
William Brien
James Brierley
Dale Brown
John Bryson
Ronald Burkes
Marcus Butler
Marco Carline
Charles Catton
David Cescon
Hong Chang
William Chapman
Tanya Chawla
Christine Chen
Terry Cheng
Douglas Chepeha
Runjan Chetty
Carol Cheung
Frederick Cheung
Charles Cho
John Cho
Young-Bin Cho
James Chow
Caroline Chung
Peter Chung
Tae Bong Chung
Tulin Cil
Blaise Clarke
Sean Cleary
Catherine Coolens
Timothy Craig
Jennifer Croke
Michael Crump
Pavel Crystal

Christine Cserti-Gazdewich
Bernard Cummings
Marcelo Cypel
Gilda da Cunha Santos
Norma D’Agostino
Andrei Damyanovich
Gail Darling
Laura Dawson
John de Almeida
Marc de Perrot
Jan Delabie
Neesha Dhani
Eleftherios Diamandis
Phedias Diamandis
Robert Dinnwell
Susan Done
James Downar
Daniel Drucker
Alexandra Easson
Saibishkumar Elantholi
Parameswaran
Elena Elimova
Mary Elliott
Christine Elser
Jaime Escallon
Andrew Evans
Hannaneh Faghihfoury
Ronald Feld
Louis Fenkell
Peter Ferguson
Sarah Ferguson
Antonio Finelli
Neil Fleshner
Jeremy Freeman
Anthony Fyles
Steven Gallinger
William Geddie
Fred Gentili
Sandeep Ghai
Sangeet Ghai
Danny Ghazarian
Ralph Gilbert
Meredith Giuliani
Rebecca Gladdy
David Goldstein
Pamela Goodwin
Chiara Gorrini
Mary Gospodarowicz
 Rashmi Goswami
Anand Govindarajan
David Grant
David Green
Paul Greig
Robert Gryfe
Patrick Gullane
Abha Gupta
Vikas Gupta
Sara Hafezi-Bakhtiar
Masoom Haider
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah Hales</td>
<td>Ernie Mak</td>
<td>David Shultz</td>
<td>E Rand Simpson</td>
</tr>
<tr>
<td>Robert Hamilton</td>
<td>Myles Margolis</td>
<td>Lillian Siu</td>
<td>Joyce So</td>
</tr>
<tr>
<td>Kathy Han</td>
<td>Warren Mason</td>
<td>Anna Spreficco</td>
<td>Boraiah Sreeharsha</td>
</tr>
<tr>
<td>Anthony Hanbidge</td>
<td>Andrew Matthew</td>
<td>Srikala Sridhar</td>
<td>Teodor Stanescu</td>
</tr>
<tr>
<td>Breffni Hannon</td>
<td>Taymee May</td>
<td>Alexander Sun</td>
<td>D Robert Sutherland</td>
</tr>
<tr>
<td>Aaron Hansen</td>
<td>J Andrea McCart</td>
<td>Carol Swallow</td>
<td>Joan Sweet</td>
</tr>
<tr>
<td>Robert Heaton</td>
<td>David McCready</td>
<td>Eva Szentesgorygi</td>
<td>Tony Tadic</td>
</tr>
<tr>
<td>Aaron Hendler</td>
<td>Allison McGeer</td>
<td>Raymond Jang</td>
<td>Ian Tannock</td>
</tr>
<tr>
<td>David Hodgson</td>
<td>Ian McGilvary</td>
<td>Martin Jarem</td>
<td>Moigian Taremri</td>
</tr>
<tr>
<td>Stefan Hofer</td>
<td>Andrea McNiven</td>
<td>Bryce Taylor</td>
<td>Martina Tse</td>
</tr>
<tr>
<td>David Hogg</td>
<td>Tatiana Melnyk</td>
<td>Santhosh Thagi</td>
<td>Ants Toi</td>
</tr>
<tr>
<td>Andrew Hope</td>
<td>Cynthia Menard</td>
<td>Anne Tierens</td>
<td>Emina Torlakovic</td>
</tr>
<tr>
<td>David Hwang</td>
<td>Hans Messner</td>
<td>Ants Toi</td>
<td>John Trachtenberg</td>
</tr>
<tr>
<td>Jonathan Irish</td>
<td>Ozgur Mete</td>
<td>Richard Tsang</td>
<td>Rajkumar Vaipcy</td>
</tr>
<tr>
<td>Mohammad Islam</td>
<td>Ur Metser</td>
<td>Hubert Tsui</td>
<td>Theodorus van der Kwast</td>
</tr>
<tr>
<td>Hyun-Jung Jang</td>
<td>Fotios Michalis</td>
<td>Rajkumar Vaipcy</td>
<td>Monique van Prooijen</td>
</tr>
<tr>
<td>Raymond Jang</td>
<td>Barbara Ann Millar</td>
<td>Auro Viswabandya</td>
<td>Thomas Waddell</td>
</tr>
<tr>
<td>Jeffrey Jaskolka</td>
<td>Kim Miller</td>
<td>Thomas Waddell</td>
<td>John Waldron</td>
</tr>
<tr>
<td>Michael Jewett</td>
<td>Naomi Miller</td>
<td>Julia Wang</td>
<td>Richard Ward</td>
</tr>
<tr>
<td>Kartik Khaveri</td>
<td>Michael Milosevic</td>
<td>Richard Ward</td>
<td>Padraig Warde</td>
</tr>
<tr>
<td>Sarah Johnson</td>
<td>Eric Monteiro</td>
<td>Robert Weersink</td>
<td>David Warr</td>
</tr>
<tr>
<td>John Kachura</td>
<td>Chantal Morel</td>
<td>Alice Wei</td>
<td>Ian Weirinb</td>
</tr>
<tr>
<td>Suzanne Kamel-Reid</td>
<td>Carol-ane Moulon</td>
<td>Ian Weirinb</td>
<td>Woodrow Wells</td>
</tr>
<tr>
<td>Zahra Kassam</td>
<td>Anna Marie Mulligan</td>
<td>Mary McEwen</td>
<td>Kirsten Wentlandt</td>
</tr>
<tr>
<td>Edward Kassel</td>
<td>Kieran Murphy</td>
<td>Lawrence White</td>
<td>Daniele Winer</td>
</tr>
<tr>
<td>Ebru Kaya</td>
<td>Rumina Musani</td>
<td>Daniel Winer</td>
<td>Ian Witterick</td>
</tr>
<tr>
<td>Armand Keating</td>
<td>Riniat Nissim</td>
<td>Jason Wong</td>
<td>Rebecca Wong</td>
</tr>
<tr>
<td>Harald Keller</td>
<td>Nancy Olivier</td>
<td>Rebeca Wong</td>
<td>Robert Wood</td>
</tr>
<tr>
<td>Erin Kennedy</td>
<td>Martin O Malley</td>
<td>Robert Wood</td>
<td>Jay Wunder</td>
</tr>
<tr>
<td>Shaf Keshavjee</td>
<td>Anne O Neill</td>
<td>Jon Wunder</td>
<td>Jiong Yan</td>
</tr>
<tr>
<td>Korosh Khalili</td>
<td>Brian O Sullivan</td>
<td>Kazuhiro Yasufuku</td>
<td>Karen Yee</td>
</tr>
<tr>
<td>Tim-Rasmus Kiehl</td>
<td>Amit Oza</td>
<td>Erik Yeo</td>
<td>Erik Yeo</td>
</tr>
<tr>
<td>Dennis Kim</td>
<td>Prodipto Pal</td>
<td>Bruce Youngson</td>
<td>Bruce Youngson</td>
</tr>
<tr>
<td>John Kim</td>
<td>Sophia Pantazi</td>
<td>Alexandre Zlotta</td>
<td>Eugene Yu</td>
</tr>
<tr>
<td>Raymond Kim</td>
<td>Demetris Patsios</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tae Kyoung Kim</td>
<td>Narinder Paul</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jennifer Knox</td>
<td>Bayardo Perez-Ordonez</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyang Mi Ko</td>
<td>Andrew Pierre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hatem Krema</td>
<td>Anca Prica</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monika Krzyzanowska</td>
<td>Thomas Purdie</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vishal Kukreti</td>
<td>Fayez Quereshy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vathany Kulasingam</td>
<td>Graeme Quest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Girish Kulkarni</td>
<td>Dheeraj Rajan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supriya Kulkarni</td>
<td>A Michael Rauth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kevin Kuo</td>
<td>Albiruni Razah</td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Kuruvilla</td>
<td>Donna Reece</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stéphane Laframboise</td>
<td>G Jolie Ringash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Lam</td>
<td>Alexandra Rink</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normand Laperriere</td>
<td>Lorne Rotstein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natasha Leighl</td>
<td>Marjan Rouzakhaman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wey-Liang Leong</td>
<td>Anabel Scaramelo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daniel Létourneau</td>
<td>Heidi Schmidt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilfred Levin</td>
<td>Andre Schuh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stéphanie Lheureux</td>
<td>Jack Seki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madeline Li</td>
<td>Stefano Serra</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patricia Lindsay</td>
<td>Patricia Shaw</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Lipton</td>
<td>Nadine Shehata</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christopher Lo</td>
<td>Frances Shepherd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen Mackay</td>
<td>Liran Shlush</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Techna Institute

Techna Leadership Team

**Director, Techna Institute** David Jaffray
**Director, Clinical Processes** Howard Abrams
**Director, Operations & Engineering** Luke Brzozowski
**Director, Knowledge Transfer** Nicole Harnett
**Director, Research Faculty, Clinical** Jonathan Irish

**Director, Research Faculty, Physical Sciences** J Paul Santerre
**Director, Commercialization** Mark Taylor
**Executive Vice President, Science and Research** Christopher Paige
*role filled by Bradly Wouters as of Oct 1, 2016*

Researchers

**Design & Engineering for Health**

**Core Lead** Joseph Cafazzo

**Affiliated Faculty**
Emily Seto
Patricia Trbovich
Leonard Tse

**Guided Therapeutics**

**Core Leads**
Jonathan Irish
David Jaffray
Walter Kucharczyk

**Scientists**
Margarete Akens
Arash Zarrine-Afsar
Jinzi Zheng

**Affiliated Faculty**
Dionne Aleman
Jean-Pierre Bissonnette
Timothy Chan
Catherine Coolens
John de Almeida
Jonathan Downar
James Drake
Gabor Fichtinger
Justin Grant
Moijgan Hodaie
Andrew Hope
Mohammad Islam
Daniel Létourneau
Andres Lozano
Claire McCann
Cynthia Ménard
Kieran Murphy
Narinder Paul
Thomas Purdie
Dheeraj Rajan
Alexandra Rink
Michael Sharpe
Michael Sherar
Teodor Stanescu
Robert Weersink
Bernd Wintersperger
Kazuhiro Yasufuku

**Informatics & Communications Technology**

**Core Leads**
Igor Jurisica
Peter Rossos

**Affiliated Faculty**
Brenda Gallie
Alejandro Jadad
Michael Jewett
Gordon Tait
Christian Veillette

**Nanotechnology & Radiochemistry**

**Core Leads**
Ur Metser
Gang Zheng

**Affiliated Faculty**
John Valliant

**Photonics**

**Core Lead**
Brian Wilson

**Scientist**
Ralph DaCosta

**Affiliated Faculty**
I Alex Vitkin

---

**Researchers**

- Core Leads: 9
- Scientists: 4
- Affiliated Faculty: 37
- Total Researchers: 50

**Research Space**: 12,484 sq. ft.

**External Funding**: $12,492,230

**Total Fellows**: 24
**Graduate Students**: 39
**Total Trainees**: 63

**Total Staff**: 95

**Publications**: 279
Toronto General Research Institute

Research Council

Director, TGRI; Research Division Head (Acting), Experimental Therapeutics Mansoor Husain
Research Division Head, Advanced Diagnostics Myron Cybulsky
Research Division Head, Support, Systems & Outcomes David Urbach
Clinical Program Head, Transplantation Atul Humar
Clinical Program Head, Peter Munk Cardiac Centre Barry Rubin
Physician-in-Chief; Clinical Program Head, Medical & Community Care Edward Cole
Physician-in-Chief; Clinical Program Head, Surgical & Critical Care Shaf Keshavjee
Chair, TGRI Appointments Committee Thomas Waddell
Group Lead, Cardiovascular Douglas Lee
Group Lead, Metabolism Michael Wheeler
Group Lead, Respiratory & Critical Care Mingyao Liu
Group Lead, Communities of Health Shabbir Alibhai
Executive Director, Research Operations Lisa Alcia
Vice President, UHN and Executive Lead, TGH Scott McIntaggart
Executive Vice President, Science and Research* Christopher Paige
*role filled by Bradly Wouters as of Oct 1, 2016

Researchers

**Advanced Diagnostics**

**Senior Scientists**
- Johane Allard
- Peter Backx
- Daniel Cattran
- Myron Cybulsky
- I George Fantus
- Eleanor Fish
- Joseph Fisher
- John Floras
- Tony Lam
- Gary Lewis
- Mingyao Liu
- Kumaraswamy Nanthakumar
- York Pei
- Barry Rubin
- James Scholey
- Katherine Siminovitch
- Michael Wheeler
- Eldad Zacksenhaus
- Li Zhang

**Scientists**
- Moumita Barua
- Filio (Phyllis) Billia
- David Cherney
- Bryan Coburn
- Shannon Dunn
- Slava Epelman
- Jason Fish
- Anthony Gramolini
- Tianru Jin
- Ana Konvalinka
- Bruce Perkins
- Heather Reich
- Clinton Robbins
- Jonathan Rocheleau

**Fellows**
- 138

**Graduate Students**
- 184

**Total Trainees**
- 322

**Senior Scientists**
- 58

**Scientists**
- 33

**Affiliate Scientists**
- 46

**Assistant Scientist**
- 1

**Total Appointed Researchers**
- 138

**Clinical Researchers**
- 235

**Total Researchers**
- 373

**Research Space**
- 237,840 sq. ft.

**External Funding**
- $83,018,937

**Total Staff**
- 456

**Publications**
- 1,308

**External Funding**
- $83,018,937
Leslie Lilly
Jessica Liu
Louis Wing Cheong Liu
Alexander Logan
Donna Lowe
Kelly MacDonald
Thomas MacMillan
Christine Maheu
Susanna Mak
Tony Mazzulli
Stuart McCluskey
Michael McDonald
Heather McDonald-Blumer
Michaël McInnis
Martin McNeeley
Robin McLeod
Rory McQuillan
Karen McRae
Sangeeta Mehta
Massimiliano Meineri
Ravi Menezes
Leonid Minkovich
Shikha Mittoo
Ravi Mohan
Matthew Morgan
Andrew Morris
Istvan Musci
Patricia Murphy
Emily Musing
Krishnakumar Nair
Gillian Nesbitt
Gary Newton
Elzie Nguyen
Geoffrey Nguyen
Peter Nielsen
Marta Novak
Enwin Oechslin
Gerald O’Leary
George Oreopoulos
Mark Osten
Mirek Otremba
Maral Ouzounian
Christopher Overgaard
Andrea Page
Blake Papsin
John Parker
Jesse Pasternak
Jacob Pendergrast
Todd Penner
David Pothier
Lisa Puchalski Ritchie
Harry Rakowski
Anthony Ralph-Edwards
Marciano Reis
Eberhard Renner
Ravi Retnakaran
Robert Richardson
Michael Robinette
Gail Robinson
S Lucy Roche
Graham Roche-Nagle
Patrik Rogalla
Peter Rossos
John Rutka
Irving Salit
Gonzalo Sapisochin
Zion Sasson
Jeffrey Schiff
Leonard Schwartz
Joerg Schwock
Phillip Segal
Peter Seidelin
Rita Selby
Mohammad Shafiee
Shane Shapera
Eran Shlomovitz
Naveed Siddiqui
Michael Sidiropoulos
Mark Silverberg
Candice Silversides
Lianne Singer
Samir Sinha
Anna Skorczewska
Peter Slinger
Kenneth Sniderman
Miranda So
Sanjeev Sockalingam
Danna Spears
Coimbatore Srinivas
Andrew Steel
A Hillary Steinhardt
Marshall Sussman
Adrienne Tan
Kong Teng Tan
John Thenganatt
Seng Thipphavong
Lianne Tile
Kathryn Tinckam
Kathryn Trottier
Wendy Tsang
Alice Tseng
Jacob Udell
Amar Uxa
Glen Van Arsdell
Annette Vegas
Allan Vescan
Rachel Wald
Paul Waldfish
Marcin Wasowicz
Cynthia Whitehead
Duminda Wijesundera
Stephen Wolman
Pui-Yuen Wong
Anna Woo
Linda Wright
Robert Wu
Paul Yip
Bernard Zinman
Toronto Rehabilitation Institute

Researchers

**Acquired Brain Injury & Society**

**Senior Scientists**
- Mark Bayley
- Angela Colantonio

**Scientist**
- Nora Cullen

**Affiliate Scientists**
- Deirdre Dawson
- Emily Nalder
- Mary Stergiou-Kita

**Artificial Intelligence & Robotics for Rehabilitation**

**Senior Scientist**
- Alex Mihailidis

**Brain Discovery & Recovery**

**Senior Scientists**
- Robin Green

**Affiliate Scientists**
- Doug Richards
- Jennifer Steeves

**Scientists**
- Goldie Nejat
- Pascal Poupart
- Rosemary Ricciardelli
- Rosalie Wang

**Cardiorespiratory Fitness**

**Senior Scientists**
- David Alter
- Sherry Grace

**Scientists**
- Tracey Colella
- Paul Oh

**Research Advisory Committee (RAC)**

*Director, TRI; Chair, RAC* Geoff Fernie

*Associate Academic Director of Research, TRI* Susan Jaglal

*Associate Scientific Director of Research, TRI* Milos Popovic

*Team Leaders* T Douglas Bradley, Angela Colantonio, Tilak Dutta, Robin Green, Avril Mansfield, Katherine McGilton, Alex Mihailidis, Paul Oh, Milos Popovic, Catriona Steele, Yana Yunusova

*Sub-Committee Chairs* Catherine Craven, Susan Jaglal, Katherine McGilton, Milos Popovic

*Business Development & Organization Effectiveness* Catharine Hancharek

*Research Services & Operations* Lois Ward

*Senior Vice President, UHN and Executive Lead, TR* Susan Jewell

*Executive Vice President, Science and Research* Christopher Paige

*role filled by Bradley Wouters as of Oct 1, 2016*

---

**Total Appointed Researchers** 110

**Senior Scientists** 23

**Scientists** 22

**Affiliate Scientists** 65

**Research Space** 65,378 sq. ft.

**Total Staff** 117

**Fellows** 30

**Graduate Students** 93

**Total Trainees** 123

**External Funding** $17,551,095

**Publications** 445
Affiliate Scientists
Jack Goodman
Krista Lanctôt
Scott Thomas

Communication
Senior Scientists
Elizabeth Rochon
Yana Yunusova
Scientist
Frank Rudzicz
Affiliate Scientists
Melanie Baljko
Boaz Ben-David
Craig Chambers
Tom Chau
Petros Faloutsos
Karen Gordon
Julie Mendelson
Aravind Namaskivayam
Kathleen Pichora-Fuller
Frank Russo
Gurjit Singh
Pascal van Liershout

Home, Community & Institutional Environments
Senior Scientists
Geoff Fernie
Andrea Furlan
Scientist
Jennifer Campos
Tilak Dutta
Bruce Haycock
Behrang Keshavarz
Alison Novak
Christine Novak
Affiliate Scientists
Veronique Boscart
Karen Gordon
Dinesh Kumbhare
Matthew Muller
Hani Naguib
Donald Philip
Veronica Wadey

Mobility
Senior Scientists
Dina Brooks
Brian Maki
William McIlroy’
W Darlene Reid
Scientist
William Gage
Avril Mansfield
Kara Patterson
Affiliate Scientists
Alastair Flint
Mary Fox
Jesse Hoey
Andrea Iaboni
Andrew Laing
Sunita Mathur
Laura Middleton
George Mochizuki
Stephen Perry
James Pratt
Karl Zabjek

Neural Engineering & Therapeutics
Senior Scientists
B Catharine Craven
Milos Popovic
Scientist
César Márquez-Chin
Kei Masani
Kristin Musselman
Jose Zariffa
Affiliate Scientists
Sandra Black
Julio Furlan
Lora Giangregorio
Sander Hitzig
Pamela Houghton
Mary Nagai
Ethne Nussbaum
Linda Rapson
Molly Verrier
Timothy Welsh
Paul Yoo

Optimization of the Rehab System
Senior Scientists
Mark Bayley
Cheryl Cott
Andrea Furlan
Susan Jaglal
Pia Kontos
Katherine McGilton
I Gary Naglie
Scientist
Shabbir Alibhai
Nora Cullen
Walter Wodchis
Affiliate Scientists
G Ross Baker
Veronique Boscart
Jill Cameron
Mary Fox
Nancy Salbach
Kathryn Sibley

Sleep Science
Senior Scientists
T Douglas Bradley

Swallowing Science
Senior Scientists
Catriona Steele
Affiliate Scientists
Lisa Duizer

Clinical Researchers
Julia Alleyne
Anthony Burns
Colleen McGIllivray
Denyse Richardson
Harpreet Sangha
Gaëtan Tardif
### UHN Research Committees

**Biomedical Research Ethics Board: Panel A**
- Alan Barolet (Chair)
- Sharon Braganza
- Daniel Buchman
- Kim Cadario
- Derek Cathcart
- Robert Cusimano
- Seema David
- Erin Dobbelsteyn
- James Downar
- Scott Fung
- Peter Giacobbe
- Andrew Ha
- Jane Lui
- Connie Marras (Vice Chair)
- Heather Sampson
- Samantha Sonshine
- Carl Virtanen
- Jean Wang
- Duminda Wijeysundera
- Noe Zamel

**Cancer Clinical Research Unit Management Committee**
- Chantale Blattler
- Karen Chadwick
- Bholy Chaudhary
- Heather Cole
- Pamela Degendorfer (Chair)
- Jeff Doi
- Marcia Flynn-Post
- Jasmine Grant
- Julie Gundy
- Sisi Jia
- Tuula Kalliomäki
- Jennifer Li
- Karen Ng
- Gerard Paras
- Nishita Parekh
- Michele Petrovic (Interim)
- Lindsay Philip
- Jesus Piza-Rodriguez
- Tracey Powell
- Menaka Pulandiran
- Kendra Ross
- Maria Schlag
- Susanna Sellmann (Chair)
- Vanessa Speers
- Marissa Tang Fong
- Ruth Turner
- Tracy Wong (Interim)
- Celeste Yu

**Cancer Registry and Data Access Committee**
- Niki Agelastos (Committee Secretariat)
- James Brierley (Chair)
- Carol Cheung
- Darlene Dale (Co-Chair)
- Alexandra Easson
- Calven Eggert
- David Goldstein
- David Hodgson
- Monika Krzyzanowska
- John Kuruvilla
- Tony Panzarella
- Bayardo Perez-Ordonez

**Clinical Studies Quality Committee**
- Lisa Alcia
- Charles Chan (Co-Chair)
- John Floras
- Carole Garmaise
- John Granton
- Jin Huh
- Deepali Kumar
- Paul MacPherson
- Paul Oh
- Amit Oza
- Christopher Paige (Co-Chair)
- Patrik Rogalla
- Katie Roposa
- David Urbach
- Sharon Walmsley

**Data Safety Monitoring Board**
- Mary Anne Chappell
- Heather Cole (ex officio)
- Kathy Han
- Krystal Internicola (ex officio)
- Haiyan Jiang
- Girish Kulkarni
- John Kuruvilla
- Srikala Sridhar (Chair)
- Ruth Turner

**Krembil Appointments Committee**
- Elizabeth Badley
- Peter Carlen
- Karen Davis
- James Eubanks
- Andres Lozano (Chair)
- Valerie Wallace
- Donald Weaver

**Krembil Clinician Investigator Appointments Committee**
- Mary Pat McAndrews
- Y Raja Rampersaud
- Antonio Strafella
- Donald Weaver (Chair)

**Krembil Space Committee**
- Elizabeth Badley
- Karen Davis
- James Eubanks (Chair)
- Ian McDermott
- Frank Vidic
- Valerie Wallace
- Donald Weaver
- Joan Wither

**Oncology Research Ethics Board: Panel B**
- Kyle Anstey
- Alan Barolet (Chair)
- Ruth Anne Baron
- David Barth (Vice Chair)
- David Cherney
- Sean Cleary
- Natasha Danson
- Nigil Haroon
- Magdy Hassouna
- Michael Hutcheon
- Stephanie Kellowan
- Charmaine Lok
- Roger McIntyre
- Ali Naraghi
- Todd Orvitz
- John Parker
- Ron Seto
- Morris Sherman
- Lorisa Stein
- Naomi Visanji

**Krembil Trainee Affairs Committee**
- Anna Badner
- Jason Charish
- Robert Chen
- Jonathon Chio
- Leanne Da Costa
- Aidan Dineen
- Rachel Dragas
- Helal Endisha
- Alexandre Guet-McCreight
- William Hutchison
- Igri Kolaj
- Alex Laliberte
- Amy Ma
- Mary Pat McAndrews
- Carley McPherson
- Samira Patel
- Johanna Ponnuthurai
- Anton Rogachov
- Kairavi Shah
- Ahad Siddiqui
- Frances Skinner (Chair)
- Manoj Vasudeva
- Julie Wan
- Joan Wither
- Meital Yerushalmi
- Zhenbo Zhang

**Krembil Appointments Committee**
- Elizabeth Badley
- Peter Carlen
- Karen Davis
- James Eubanks
- Andres Lozano (Chair)
- Valerie Wallace
- Donald Weaver

**Krembil Clinician Investigator Appointments Committee**
- Mary Pat McAndrews
- Y Raja Rampersaud
- Antonio Strafella
- Donald Weaver (Chair)

**Krembil Space Committee**
- Elizabeth Badley
- Karen Davis
- James Eubanks (Chair)
- Ian McDermott
- Frank Vidic
- Valerie Wallace
- Donald Weaver
- Joan Wither

**Clinical Studies Quality Committee**
- Lisa Alcia
- Charles Chan (Co-Chair)
- John Floras
- Carole Garmaise
- John Granton
- Jin Huh
- Deepali Kumar
- Paul MacPherson
- Paul Oh
- Amit Oza
- Christopher Paige (Co-Chair)
- Patrik Rogalla
- Katie Roposa
- David Urbach
- Sharon Walmsley

**Data Safety Monitoring Board**
- Mary Anne Chappell
- Heather Cole (ex officio)
- Kathy Han
- Krystal Internicola (ex officio)
- Haiyan Jiang
- Girish Kulkarni
- John Kuruvilla
- Srikala Sridhar (Chair)
- Ruth Turner

**Krembil Appointments Committee**
- Elizabeth Badley
- Peter Carlen
- Karen Davis
- James Eubanks
- Andres Lozano (Chair)
- Valerie Wallace
- Donald Weaver

**Krembil Clinician Investigator Appointments Committee**
- Mary Pat McAndrews
- Y Raja Rampersaud
- Antonio Strafella
- Donald Weaver (Chair)

**Krembil Space Committee**
- Elizabeth Badley
- Karen Davis
- James Eubanks (Chair)
- Ian McDermott
- Frank Vidic
- Valerie Wallace
- Donald Weaver
- Joan Wither

**Clinical Studies Quality Committee**
- Lisa Alcia
- Charles Chan (Co-Chair)
- John Floras
- Carole Garmaise
- John Granton
- Jin Huh
- Deepali Kumar
- Paul MacPherson
- Paul Oh
- Amit Oza
- Christopher Paige (Co-Chair)
- Patrik Rogalla
- Katie Roposa
- David Urbach
- Sharon Walmsley

**Data Safety Monitoring Board**
- Mary Anne Chappell
- Heather Cole (ex officio)
- Kathy Han
- Krystal Internicola (ex officio)
- Haiyan Jiang
- Girish Kulkarni
- John Kuruvilla
- Srikala Sridhar (Chair)
- Ruth Turner
<table>
<thead>
<tr>
<th>Committee</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PM Appointments Committee</strong></td>
<td>Santhosh Thyagu, Ruth Turner, Razq Hakem, Richard Hill, Norman Iscove, David Jaffray, Rama Khokha (Chair), Tak Mak, Mark Minden, Gilbert Prévé, Gary Rodin, Robert Rottapel, Vuk Stambolic, Bradly Wouters</td>
</tr>
<tr>
<td><strong>PM Equipment Committee</strong></td>
<td>Laurie Ailles, Mitsuhiko Ikura, Rama Khokha, Thomas Kislinger, Trevor Pugh, Robert Rottapel, Malcolm Smith, Ming-Sound Tsao, Brian Wilson (Chair), Patrick Yau</td>
</tr>
<tr>
<td><strong>PM Space Committee</strong></td>
<td>Michael Hoffman, Mitsuhiko Ikura, Rama Khokha, Pamela Ohashi (Chair), Gary Rodin, Aaron Schimmer</td>
</tr>
<tr>
<td><strong>Radionuclide Safety Committee</strong></td>
<td>Shelley Belford, Jonathan Brotchie, Gina Capone, Perry Chong, Mary Fountas, Judy Gabrys (Co-Chair), Mihaela Gnj, David Green, Norman Iscove, Ian McDermott, Ur Metser, Jerry Plastino, Deborah Scollard, Frank Tourneur (Co-Chair), Li Zhang</td>
</tr>
<tr>
<td><strong>Rehabilitation Medicine and Science Research Ethics Board: Panel D</strong></td>
<td>Puja Ahiuluvalia, Tania Artian, Jeffery Baine, Carly Barbon, Jennifer Boger (on leave), Anthony Burns, Tracey Colella, Carol Fancott, Heather Flett, Diana Frasok, Igor Gontcharov, Susan Gorski, Lindsay Green-Noble, Ann Heesters (Chair), Shadi Katirai (on leave), Pia Kontos, Avril Mansfield, César Márquez-Chin, Kei Masani, Nadia Meli, Ashwini Namasiyam, Diane Nixon (on leave), Stephanie Nixon, Paul Oh (Vice Chair), Archna Patel, Linda Penoyer (on leave), Marta Pesin, Karen SASAKI, Kathryn Sibley, Catriona Steele, Shauna Stokely, Yervant Terzian, Daniel Vena, Rosalie Wang, Rosalind Waxman, Nykema Wright, Lesley Wyllie, Audrey Yap</td>
</tr>
<tr>
<td><strong>Research Biosafety Committee</strong></td>
<td>Lorraine Kalia, Camille Lemieux, Jeanette MacLean (ex officio), Ian McDermott (ex officio), Badru Moloo (ex officio), Gilbert Privé, John Shannon (Acting Chair)</td>
</tr>
<tr>
<td><strong>Research Risk and Audit Committee</strong></td>
<td>Lisa Alcia (Chair), Chip Campbell, Gabriella Fischer, Tom Goldthorpe, Tony Goncalves, Alex Karabanow, Amy Ma, Paul Macpherson, Carley Macpherson, Ian McDermott, Peggy McGill, Kathy McGilton, Tracy Mcquire, Badru Moloo, Lisa Murphy, Christopher Paige, Katie Roposa (Co-Chair), Evelina Rutzowski, Gianfranco Scipione, Ania Sengar, John Shannon, Alena Sjarheyeva, Mike Voth, Lois Ward, Tania Yousaf</td>
</tr>
<tr>
<td><strong>TGRI Appointments Committee</strong></td>
<td>David Cherney, Angela Cheung, Myron Cybulsky, Shannan Dunn, Anna Gagliardi, Margaret Herridge, Mansoor Husain, Christopher Paige, David Urbach, Thomas Waddell (Chair), Minna Woo</td>
</tr>
<tr>
<td><strong>TRI Junior Scientists’ Support &amp; Mentorship Committee</strong></td>
<td>Tracey Colella, Susan Jaglal (Chair), Avril Mansfield, Lois Ward, Azadeh Yadollahi</td>
</tr>
<tr>
<td><strong>TRI Scientists’ Productivity &amp; Promotions Committee</strong></td>
<td>Geoff Fernie, Susan Jaglal (Chair), Milos Popovic (Chair)</td>
</tr>
<tr>
<td><strong>TRI Standard Operating Procedures Committee</strong></td>
<td>Jennifer Campos, Geoff Fernie (Co-Chair), Catharine Hancharek, Susan Jaglal, Katherine McGilton (Co-Chair), Milos Popovic, Lois Ward</td>
</tr>
<tr>
<td><strong>TRI Students’ Support &amp; Mentorship Committee</strong></td>
<td>Susan Jaglal (Chair), Johanna Ponnuthurai, Lois Ward</td>
</tr>
<tr>
<td><strong>TRI Team Leaders’ Committee</strong></td>
<td>T Douglas Bradley, Angela Colantonio, B Catharine Craven, Tilak Dutta, Geoff Fernie (Chair), Robin Green, Catharine Hancharek (ex officio), Susan Jaglal, Avril Mansfield, Katherine McGilton, Alex Mihailidis, Paul Oh, Milos Popovic, Catriona Steele, Yana Yunusova</td>
</tr>
<tr>
<td><strong>TRI Team Leadership &amp; Productivity Committee</strong></td>
<td>Geoff Fernie, Susan Jaglal, Milos Popovic (Chair)</td>
</tr>
<tr>
<td>External Sponsors</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>Baxter Healthcare</td>
</tr>
<tr>
<td>AbbVie Corporation</td>
<td>Bayer</td>
</tr>
<tr>
<td>Abiomed</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td>Acetly</td>
<td>Beth Israel Deaconess Medical Center</td>
</tr>
<tr>
<td>Acetylon Pharmaceuticals</td>
<td>BioCanRX</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals</td>
<td>Biocompatibles UK</td>
</tr>
<tr>
<td>ActiveO</td>
<td>BioDiscovery Toronto</td>
</tr>
<tr>
<td>Adamas Pharmaceuticals</td>
<td>Biogen</td>
</tr>
<tr>
<td>Aeglea Biotherapeutics</td>
<td>Biotronik</td>
</tr>
<tr>
<td>AGA Medical</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Agensys</td>
<td>Boston Biomedical</td>
</tr>
<tr>
<td>AGE-WELL</td>
<td>Boston Medical Center</td>
</tr>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Boston Scientific</td>
</tr>
<tr>
<td>AKR Development</td>
<td>Bracco Diagnostics</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>Brain Canada</td>
</tr>
<tr>
<td>Alfred Health</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Alpha Cancer Technologies</td>
<td>British Columbia Cancer Agency</td>
</tr>
<tr>
<td>Alzheimer Society of Canada</td>
<td>Canada Foundation for Innovation</td>
</tr>
<tr>
<td>Alzheimer’s Association</td>
<td>Canada Research Chairs Program</td>
</tr>
<tr>
<td>Ambit Biosciences</td>
<td>Canadian Agency for Drugs and Technologies in Health</td>
</tr>
<tr>
<td>American Association for Hand Surgery</td>
<td>Canadian Anesthesiologists’ Society</td>
</tr>
<tr>
<td>American Association for Thoracic Surgery</td>
<td>Canadian Association of Gastroenterology</td>
</tr>
<tr>
<td>American Association of Neurological Surgeons</td>
<td>Canadian Association of Psychosocial Oncology</td>
</tr>
<tr>
<td>American Brain Foundation</td>
<td>Canadian Association of Radiation Oncology</td>
</tr>
<tr>
<td>American College of Rheumatology</td>
<td>Canadian Blood and Marrow Transplant Group</td>
</tr>
<tr>
<td>American Medical Systems Europe BV</td>
<td>Canadian Blood Services</td>
</tr>
<tr>
<td>American Society for Bone and Mineral Research</td>
<td>Canadian Breast Cancer Foundation</td>
</tr>
<tr>
<td>American Society of Clinical Oncology</td>
<td>Canadian Cancer Society Research Institute</td>
</tr>
<tr>
<td>American Society of Hematology</td>
<td>Canadian Diabetes Association</td>
</tr>
<tr>
<td>American Society of Transplant Surgeons</td>
<td>Canadian Foundation for AIDS Research</td>
</tr>
<tr>
<td>American Thoracic Society</td>
<td>Canadian Frailty Network</td>
</tr>
<tr>
<td>American Urological Association</td>
<td>Canadian Heart Research Centre</td>
</tr>
<tr>
<td>Amgen</td>
<td>Canadian Institutes of Health Research</td>
</tr>
<tr>
<td>Anesthesia Patient Safety Foundation</td>
<td>Canadian Liver Foundation</td>
</tr>
<tr>
<td>Anthera Pharmaceuticals</td>
<td>Canadian National Transplant Research Program</td>
</tr>
<tr>
<td>AOSpine</td>
<td>Canadian Occupational Therapy Foundation</td>
</tr>
<tr>
<td>APOCARE Pharma</td>
<td>Canadian Partnership Against Cancer</td>
</tr>
<tr>
<td>Apteose Biosciences</td>
<td>Canadian Psychological Association</td>
</tr>
<tr>
<td>Aragon Pharmaceuticals</td>
<td>Canadian Society of Hospital Pharmacists</td>
</tr>
<tr>
<td>Arbutus Biopharma</td>
<td>Cancer Care Ontario</td>
</tr>
<tr>
<td>Arthritis Research Foundation</td>
<td>Cancer Research Institute</td>
</tr>
<tr>
<td>Associated Medical Services</td>
<td>Cancer Research Society</td>
</tr>
<tr>
<td>Association of University Radiologists</td>
<td>Capital Health - Nova Scotia</td>
</tr>
<tr>
<td>Astellas Pharma</td>
<td>Health Authority</td>
</tr>
<tr>
<td>Astex Pharmaceuticals</td>
<td>Cardiac Care Network of Ontario</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Carestream Health</td>
</tr>
<tr>
<td>Avarin Pharmaceuticals</td>
<td>Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>Barbara Ann Karmanos Cancer Institute</td>
<td>Celator Pharmaceuticals</td>
</tr>
<tr>
<td>Bavarian Nordic</td>
<td>Celgene</td>
</tr>
<tr>
<td>Beckman Coulter</td>
<td>Centre for Addiction and Mental Health</td>
</tr>
<tr>
<td>Beth Israel Deaconess Medical Center</td>
<td>Centre for Commercialization of Regenerative Medicine</td>
</tr>
<tr>
<td>BioDiscovery Toronto</td>
<td>Centre for Probe Development and Commercialization</td>
</tr>
<tr>
<td>Biogen</td>
<td>Centre hospitalier de l’Université de Montréal</td>
</tr>
<tr>
<td>Biotronik</td>
<td>Cervical Spine Research Society</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td>Boston Biomedical</td>
<td>Chimexir</td>
</tr>
<tr>
<td>Boston Medical Center</td>
<td>CIHR Canadian HIV Trials Network</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>Bracco Diagnostics</td>
<td>Clinique La Prairie</td>
</tr>
<tr>
<td>Brain Canada</td>
<td>Columbia University</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Conquer Paralysis Now</td>
</tr>
<tr>
<td>British Columbia Cancer Agency</td>
<td>Cook Group</td>
</tr>
<tr>
<td>Canada Foundation for Innovation</td>
<td>Craig H. Neilsen Foundation</td>
</tr>
<tr>
<td>Canada Research Chairs Program</td>
<td>CSL Behring</td>
</tr>
<tr>
<td>Canadian Agency for Drugs and Technologies in Health</td>
<td>Cystic Fibrosis Canada</td>
</tr>
<tr>
<td>Canadian Anesthesiologists’ Society</td>
<td>Daichi Sankyo</td>
</tr>
<tr>
<td>Canadian Association of Gastroenterology</td>
<td>Dartmouth College</td>
</tr>
<tr>
<td>Canadian Association of Psychosocial Oncology</td>
<td>Duke University</td>
</tr>
<tr>
<td>Canadian Association of Radiation Oncology</td>
<td>Dystonia Medical Research Foundation</td>
</tr>
<tr>
<td>Canadian Blood and Marrow Transplant Group</td>
<td>Edwards Lifesciences</td>
</tr>
<tr>
<td>Canadian Blood Services</td>
<td>Eisai</td>
</tr>
<tr>
<td>Canadian Breast Cancer Foundation</td>
<td>Eli Lilly Canada</td>
</tr>
<tr>
<td>Canadian Cancer Society Research Institute</td>
<td>Epilepsy Canada</td>
</tr>
<tr>
<td>Canadian Diabetes Association</td>
<td>European Organisation for Research and Treatment of Cancer</td>
</tr>
<tr>
<td>Canadian Foundation for AIDS Research</td>
<td>Exelixis</td>
</tr>
<tr>
<td>Canadian Frailty Network</td>
<td>Ferring Pharmaceuticals</td>
</tr>
<tr>
<td>Canadian Heart Research Centre</td>
<td>Foundation Fighting Blindness</td>
</tr>
<tr>
<td>Canadian Institutes of Health Research</td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td>Canadian Liver Foundation</td>
<td>GBM/CIDP Foundation International</td>
</tr>
<tr>
<td>Canadian National Transplant Research Program</td>
<td>GE Canada</td>
</tr>
<tr>
<td>Canadian Occupational Therapy Foundation</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>Canadian Partnership Against Cancer</td>
<td>Genentech</td>
</tr>
<tr>
<td>Canadian Psychological Association</td>
<td>Generex Biotechnology</td>
</tr>
<tr>
<td>Canadian Society of Hospital Pharmacists</td>
<td>Genome Canada</td>
</tr>
<tr>
<td>Cancer Care Ontario</td>
<td>Genzyme Canada</td>
</tr>
<tr>
<td>Cancer Research Institute</td>
<td>Gilead Sciences</td>
</tr>
<tr>
<td>Cancer Research Society</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Capital Health - Nova Scotia</td>
<td>Global Affairs Canada</td>
</tr>
<tr>
<td>Health Authority</td>
<td>Grand Challenges Canada</td>
</tr>
<tr>
<td>Cardiac Care Network of Ontario</td>
<td>Grifols</td>
</tr>
<tr>
<td>Carestream Health</td>
<td>Hackensack University Medical Center</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>Hamilton Health Sciences</td>
</tr>
<tr>
<td>Celator Pharmaceuticals</td>
<td>Health Quality Ontario</td>
</tr>
<tr>
<td>Celgene</td>
<td>Health Technology Exchange</td>
</tr>
<tr>
<td>Centre for Addiction and Mental Health</td>
<td>Heart and Stroke Foundation of Canada</td>
</tr>
<tr>
<td>Centre for Commercialization of Regenerative Medicine</td>
<td>Heart and Stroke Foundation of Ontario</td>
</tr>
<tr>
<td>Centre for Probe Development and Commercialization</td>
<td>Hemostemix</td>
</tr>
<tr>
<td>Centre hospitalier de l’Université de Montréal</td>
<td>Henry Ford Health System</td>
</tr>
<tr>
<td>Cervical Spine Research Society</td>
<td>Horizon Pharma</td>
</tr>
<tr>
<td>Children’s Hospital of Philadelphia</td>
<td>Hospira</td>
</tr>
<tr>
<td>Chimexir</td>
<td>HSF Canadian Partnership for Stroke Recovery</td>
</tr>
<tr>
<td>CIHR Canadian HIV Trials Network</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>Cincinnati Children's Hospital Medical Center</td>
<td>Imagistx</td>
</tr>
<tr>
<td>Clinique La Prairie</td>
<td>INC Research</td>
</tr>
<tr>
<td>Columbia University</td>
<td>Insmed</td>
</tr>
<tr>
<td>Conquer Paralysis Now</td>
<td>Institut de recherche Robert-Sauvé en santé et en sécurité du travail</td>
</tr>
<tr>
<td>Cook Group</td>
<td>Institut universitaire de cardiologie et de pneumologie de Québec</td>
</tr>
<tr>
<td>Craig H. Neilsen Foundation</td>
<td>Institute for Clinical Evaluative Sciences</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Integrative Biology of Breast Cancer Research Centre</td>
</tr>
<tr>
<td>Cystic Fibrosis Canada</td>
<td>Intercept Pharmaceuticals</td>
</tr>
<tr>
<td>Daichi Sankyo</td>
<td>International Parkinson and Movement Disorder Society</td>
</tr>
<tr>
<td>Dartmouth College</td>
<td>Israel Cancer Research Fund</td>
</tr>
<tr>
<td>Duke University</td>
<td>J.P. Bickell Foundation</td>
</tr>
<tr>
<td>Dystonia Medical Research Foundation</td>
<td>Jaeb Center for Health Research</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Janssen</td>
</tr>
<tr>
<td>Eisai</td>
<td>Jewish General Hospital</td>
</tr>
<tr>
<td>Eli Lilly Canada</td>
<td>John Wiley and Sons</td>
</tr>
<tr>
<td>Epilepsy Canada</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>European Organisation for Research and Treatment of Cancer</td>
<td>JSS Medical Research</td>
</tr>
<tr>
<td>Exelixis</td>
<td>Juvenile Diabetes Research Foundation Canada</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals</td>
<td>Karyopharm Therapeutics</td>
</tr>
<tr>
<td>Foundation Fighting Blindness</td>
<td>Kiadis Pharma</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Kidney Cancer Canada</td>
</tr>
<tr>
<td>GBM/CIDP Foundation International</td>
<td>Krembil Foundation</td>
</tr>
<tr>
<td>GE Canada</td>
<td>Kyowa Hakko Kirin</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>Lahey Clinic Foundation</td>
</tr>
<tr>
<td>Genentech</td>
<td>Lawson Health Research Institute</td>
</tr>
<tr>
<td>Generex Biotechnology</td>
<td>Leukemia and Lymphoma Society</td>
</tr>
<tr>
<td>Genome Canada</td>
<td>Leukemia Research Foundation of Canada</td>
</tr>
<tr>
<td>Genzyme Canada</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Global Affairs Canada</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Health Authority</td>
<td>Grand Challenges Canada</td>
</tr>
<tr>
<td>Cardiac Care Network of Ontario</td>
<td>Grifols</td>
</tr>
<tr>
<td>Carestream Health</td>
<td>Hackensack University Medical Center</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>Hamilton Health Sciences</td>
</tr>
<tr>
<td>Celator Pharmaceuticals</td>
<td>Health Quality Ontario</td>
</tr>
<tr>
<td>Celgene</td>
<td>Health Technology Exchange</td>
</tr>
<tr>
<td>Centre for Addiction and Mental Health</td>
<td>Heart and Stroke Foundation of Canada</td>
</tr>
<tr>
<td>Centre for Commercialization of Regenerative Medicine</td>
<td>Heart and Stroke Foundation of Ontario</td>
</tr>
<tr>
<td>Centre for Probe Development and Commercialization</td>
<td>Hemostemix</td>
</tr>
<tr>
<td>Centre hospitalier de l’Université de Montréal</td>
<td>Henry Ford Health System</td>
</tr>
<tr>
<td>Cervical Spine Research Society</td>
<td>Horizon Pharma</td>
</tr>
<tr>
<td>Children’s Hospital of Philadelphia</td>
<td>Hospira</td>
</tr>
<tr>
<td>Chimexir</td>
<td>HSF Canadian Partnership for Stroke Recovery</td>
</tr>
<tr>
<td>CIHR Canadian HIV Trials Network</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>Canadian Association of Rheumatology</td>
<td>Imagistx</td>
</tr>
<tr>
<td>Canadian Association of Gastroenterology</td>
<td>INC Research</td>
</tr>
<tr>
<td>Canadian Association of Psychosocial Oncology</td>
<td>Insmed</td>
</tr>
<tr>
<td>Canadian Association of Radiation Oncology</td>
<td>Institut de recherche Robert-Sauvé en santé et en sécurité du travail</td>
</tr>
<tr>
<td>Canadian Blood and Marrow Transplant Group</td>
<td>Institut universitaire de cardiologie et de pneumologie de Québec</td>
</tr>
<tr>
<td>Canadian Blood Services</td>
<td>Institute for Clinical Evaluative Sciences</td>
</tr>
<tr>
<td>Canadian Breast Cancer Foundation</td>
<td>Integrative Biology of Breast Cancer Research Centre</td>
</tr>
<tr>
<td>Canadian Cancer Society Research Institute</td>
<td>Intercept Pharmaceuticals</td>
</tr>
<tr>
<td>Canadian Diabetes Association</td>
<td>International Parkinson and Movement Disorder Society</td>
</tr>
<tr>
<td>Canadian Foundation for AIDS Research</td>
<td>Israel Cancer Research Fund</td>
</tr>
<tr>
<td>Canadian Frailty Network</td>
<td>J.P. Bickell Foundation</td>
</tr>
<tr>
<td>Canadian Heart Research Centre</td>
<td>Jaeb Center for Health Research</td>
</tr>
<tr>
<td>Canadian Institutes of Health Research</td>
<td>Janssen</td>
</tr>
<tr>
<td>Canadian Liver Foundation</td>
<td>Jewish General Hospital</td>
</tr>
<tr>
<td>Canadian National Transplant Research Program</td>
<td>John Wiley and Sons</td>
</tr>
<tr>
<td>Canadian Occupational Therapy Foundation</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Canadian Partnership Against Cancer</td>
<td>JSS Medical Research</td>
</tr>
<tr>
<td>Canadian Psychological Association</td>
<td>Juvenile Diabetes Research Foundation Canada</td>
</tr>
<tr>
<td>Canadian Society of Hospital Pharmacists</td>
<td>Karyopharm Therapeutics</td>
</tr>
<tr>
<td>Cancer Care Ontario</td>
<td>Kiadis Pharma</td>
</tr>
<tr>
<td>Cancer Research Institute</td>
<td>Kidney Cancer Canada</td>
</tr>
<tr>
<td>Cancer Research Society</td>
<td>Krembil Foundation</td>
</tr>
<tr>
<td>Capital Health - Nova Scotia</td>
<td>Kyowa Hakko Kirin</td>
</tr>
<tr>
<td>Health Authority</td>
<td>Lahey Clinic Foundation</td>
</tr>
<tr>
<td>Cardiac Care Network of Ontario</td>
<td>Lawson Health Research Institute</td>
</tr>
<tr>
<td>Carestream Health</td>
<td>Leukemia and Lymphoma Society</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>Leukemia Research Foundation of Canada</td>
</tr>
<tr>
<td>Celator Pharmaceuticals</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Celgene</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Centre for Addiction and Mental Health</td>
<td>Lebanon Foundation</td>
</tr>
<tr>
<td>Centre for Commercialization of Regenerative Medicine</td>
<td>Lebanon Foundation</td>
</tr>
</tbody>
</table>
Financials 2015/2016

Total Core Research Funding $72,719,135

- Ministry of Health and Long-Term Care $3,379,700
- Other (including ancillary revenues) $16,690,082
- Grant Funding (indirect costs) $12,187,250
- UHN Foundations $36,327,810
- Rental Income $2,239,151
- Investment Income $1,895,142
- Ministry of Health and Long-Term Care $3,379,700
Total External Project Funding $308,324,800

- Other $3,213,461
- Corporate Contracts $4,362,671
- Career/Traineeship Awards $9,669,471
- Infrastructure/Maintenance Awards $23,866,880
- Clinical Studies $45,215,193
- UHN Foundations $100,273,108
- Operating Grants $121,724,016
International Research Advisory Board

Samuel Weiss, PhD (Chair)
Professor, Departments of Cell Biology & Anatomy and Physiology & Pharmacology, University of Calgary; Inaugural Director of the Hotchkiss Brain Institute

Philip E Branton, OC, PhD, FRSC
Gilman Cheney Professor, Departments of Biochemistry and Oncology and the Goodman Cancer Centre, McGill University

Thomas Rockwell Mackie, PhD
Professor Emeritus, Medical Physics and Human Oncology, University of Wisconsin; Director, Medical Devices Focus Area, Morgridge Institute for Research

Lynne Warner Stevenson, MD
Director, Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital; Professor, Harvard Medical School

John E Wennberg, MD, MPH
Active Professor Emeritus of Community & Family Medicine, Peggy Y Thomson Professor Emeritus in Evaluative Clinical Sciences and Director Emeritus and Founder, The Dartmouth Institute for Health Policy & Clinical Practice

Research Committee Board of Trustees

Independent Trustees (Voting)
Robert Krembil (Chair), John Mulvihill, Barbara Stymiest, Ken Rotman

Ex-officio Trustees (Voting)
Peter Pisters, Joy Richards, Kathryn Nichol

Others (Voting)
Marc Milgrom, Stephen Bear, Mark Krembil, Lawrence Pentland, Linda Mezon

Ex-officio Non-Trustees (Non-voting)
Christopher Paige, Justine Jackson, John Granton

Disclaimers
Publications, Personnel, Research Committees: Publication data provided by UHN Research Program Planning & Analysis. Leadership data provided by UHN institute Business Managers. Data accurate as of September 1, 2016. Some figures may be rounded and/or may include data not represented in institute data. Publications jointly authored by investigators at multiple UHN institutes are counted only once in the UHN Research total. Researchers with more than one affiliation within an institute, or between institutes, are only included once in the total count. Metrics for each institute were calculated by considering data on all Researchers, which include CCRU or Clinical Researchers as applicable. Please note that Clinical Researchers and CCRU investigators are not formally appointed at the research institutes and are therefore not subject to the research institutes’ scientific and performance reviews. Clinical Researchers are defined as UHN staff who are listed as co-author on at least one publication in the 2015 calendar year and/or held research funding over the 2015/16 fiscal year. Drs. Crystal (page 32), Sharpe (page 34) and McIlroy (page 39) passed away in 2016.

Trainees: Institute trainee counts are accurate as of August 1, 2016 and were provided by UHN’s Office of Research Trainees. They reflect only those trainees supervised by researchers with a primary appointment at the institute and who spent more than 50% of their time at UHN.

Space: Data provided by UHN Research Facilities Planning & Safety and based on space audited by September 30, 2016 across UHN sites. Core facilities and Research Solutions and Services spaces are not included in institute space totals.

Financial Data: All figures represent the fiscal year ending March 31, 2016, and include the Krembil, PM Cancer Centre, TGRI, TRI, Techna and Research Operations. Figures have been provided by UHN Research Financial Services. Total funding includes External and Core Funding amounts and is listed within the UHN Research Snapshot on the inside front cover.

Production Credits: This report is published by the Office of the Executive Vice President, Science and Research, UHN. Graphic design, writing and production by UHN’s Strategic Research Initiatives Development Team.
**About the cover:** In business culture, silo mentality is an attitude that occurs when departments or groups within an organization work in isolation and do not share information with other individuals in the same organization. The cover image is a graphic representation of silos being broken down in a research hospital to enable sharing of knowledge between different disciplines, departments, fields and health professions—a key requirement for translating research discoveries into clinical practice. The cover photograph features the Canada Malting Silos located on the Toronto waterfront, which were built in 1928.

---

**This report was printed on environmentally friendly paper, which achieved the following savings:**

| 9 trees | 2,807 kg CO₂ |
| 8,364 L of water | 5,323 km driven |
| 90 days of water consumption | 7 MMBTU |
| 856 kg of waste | 35,184 60W light bulbs for one hour |
| 8 waste containers | 4 lb NOₓ |
| emissions of one truck over 5 days |

*Source: calculateur.rollandinc.com*